title: First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.
abstract: The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7.5, 10, 12.5, and 15 mg) administered orally once daily for 7 days. Adverse events and continuous telemetry were collected on successive panels of six patients (five active, one placebo). Acetylcholinesterase, butyrylcholinesterase, and plasma drug levels were measured. A total of 29 patients were randomized and 18 completed the study. A total of seven patients, including five of five in the 12.5-mg panel, discontinued because of adverse events. Four patients were withdrawn administratively from the first panel while an episode of atrial fibrillation (the only serious adverse event) was investigated. This panel was then repeated. Mild, transient headache or nausea were the most commonly reported adverse events. Multiple moderate adverse events in the 12.5-mg panel (including nausea, vomiting, and anorexia) led to the decision not to proceed with a 15-mg panel. Ten milligrams was determined to be the maximum tolerated dose. Ganstigmine exhibited nonlinear pharmacokinetics, was absorbed rapidly, and reached peak concentrations within 1 hour. Acetylcholinesterase inhibition was dose dependent and lasted as long as 24 hours. Ganstigmine, a novel cholinesterase inhibitor, was well tolerated within a dosing range of 5 to 10 mg. Once-daily dosing is supported by data on acetylcholinesterase inhibition.
authors.affiliation: California Clinical Trials, Beverly Hills, California USA,
authors.forename: S S
authors.initials: SS
authors.lastname: Jhee
authors.forename: Laura
authors.initials: L
authors.lastname: Fabbri
authors.forename: A
authors.initials: A
authors.lastname: Piccinno
authors.forename: P
authors.initials: P
authors.lastname: Monici
authors.forename: S
authors.initials: S
authors.lastname: Moran
authors.forename: V
authors.initials: V
authors.lastname: Zarotsky
authors.forename: E Y
authors.initials: EY
authors.lastname: Tan
authors.forename: E J
authors.initials: EJ
authors.lastname: Frackiewicz
authors.forename: T
authors.initials: T
authors.lastname: Shiovitz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000470:Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000544:Alzheimer Disease / Q000188:drug therapy*; D019540:Area Under Curve; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000470:Alkaloids; D002219:Carbamates; D002800:Cholinesterase Inhibitors; C447079:ganstigmine